Mutant alpha-synuclein causes age-dependent neuropathology in monkey brain

Journal of Neuroscience

Volumn 35, Issue 21, 2015, Pages 8345-8358

  Yang, Weili ^a   Wang, Guohao ^a,b   Wang, Chuan En ^b   Guo, Xiangyu ^a   Yin, Peng ^a   Gao, Jinquan ^a   Tu, Zhuchi ^a   Wang, Zhengbo ^c   Wu, Jing ^c   Hu, Xintian ^c   Li, Shihua ^b   Li, Xiao Jiang ^a,b  

^a INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

Aging; Degeneration; Neurite; Parkinson s; Primate

Indexed keywords

ALPHA SYNUCLEIN; BRAIN PROTEIN; MUTANT PROTEIN; NERVE CELL ADHESION MOLECULE; NEUROFASCIN; PARKIN; PROTEIN PINK1; UNCLASSIFIED DRUG;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; LEWY BODY; MOUSE; NERVE FIBER DEGENERATION; NERVE FIBER GROWTH; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RHESUS MONKEY; SUBSTANTIA NIGRA; WESTERN BLOTTING; AGING; ANIMAL; BIOSYNTHESIS; BRAIN; C57BL MOUSE; GENETICS; HAPLORHINI; MALE; METABOLISM; MUTATION; NERVE DEGENERATION; PATHOLOGY;

AGING; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; HAPLORHINI; MACACA MULATTA; MALE; MICE; MICE, INBRED C57BL; MUTATION; NERVE DEGENERATION;

EID: 84930260508     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0772-15.2015     Document Type: Article

References (43)

1. Abeywardana T, Lin YH, Rott R, Engelender S, Pratt MR (2013) Sitespecific differences in proteasome-dependent degradation of monoubiquitinated alpha-synuclein. Chem Biol 20:1207–1213.
2. Beal MF (2010) Parkinson’s disease: a model dilemma. Nature 466:S8–S10.
3. Becker G (2003) Methods for the early diagnosis of Parkinson’s disease. Nervenarzt 74:S7–S11.
4. Bendor JT, Logan TP, Edwards RH (2013) The function of alpha-synuclein. Neuron 79:1044–1066.
5. Brás J, Guerreiro R, Hardy J (2015) SnapShot: genetics of Parkinson’s disease. Cell 160:570–570.e1.
6. Brück D, Wenning GK, Stefanova N, Fellner L (2015) Glia and alphasynuclein in neurodegeneration: a complex interaction. Neurobiol Dis. In press.
7. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destée A (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 364:1167–1169.
8. Chung CY, Khurana V, Auluck PK, Tardiff DF, Mazzulli JR, Soldner F, Baru V, Lou Y, Freyzon Y, Cho S, Mungenast AE, Muffat J, Mitalipova M, Pluth MD, Jui NT, Schüle B, Lippard SJ, Tsai LH, Krainc D, Buchwald SL, Jaenisch R, Lindquist S (2013) Identification and rescue of alphasynuclein toxicity in Parkinson patient-derived neurons. Science 342: 983–987.
9. Dawson TM, Ko HS, Dawson VL (2010) Genetic animal models of Parkinson’s disease. Neuron 66:646–661.
10. Ebrahimi-Fakhari D, Cantuti-Castelvetri I, Fan Z, Rockenstein E, Masliah E, Hyman BT, McLean PJ, Unni VK (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J Neurosci 31:14508–14520.
11. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130:799–815.
12. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301.
13. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521–533.
14. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501.
15. Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H (2010) Astrocytic expression of Parkinson’s disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 3:12.
16. Gupta A, Dawson VL, Dawson TM (2008) What causes cell death in Parkinson’s disease? Ann Neurol 64:S3–S15.
17. Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D (2014) Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain 137:2493–2508.
18. Harischandra DS, Jin H, Anantharam V, Kanthasamy A, Kanthasamy AG (2015) -Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson’s disease. Toxicol Sci 143:454–468.
19. Hassel B, Rathjen FG, Volkmer H (1997) Organization of the neurofascin gene and analysis of developmentally regulated alternative splicing. J Biol Chem 272:28742–28749.
20. Kanthasamy A, Jin H, Mehrotra S, Mishra R, Kanthasamy A, Rana A (2010) Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson’s disease. Neurotoxicology 31:555–561.
21. Kriebel M, Wuchter J, Trinks S, Volkmer H (2012) Neurofascin: A switch between neuronal plasticity and stability. Int J Biochem Cell Biol 44:694– 697.
22. Lee VM, Trojanowski JQ (2006) Mechanisms of Parkinson’s disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52:33–38.
23. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron 64:807–827.
24. Lindner M, Ng JK, Hochmeister S, Meinl E, Linington C (2013) Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis. Exp Neurol 247:259–266.
25. Lo Bianco C, Ridet JL, Schneider BL, Deglon N Aebischer P (2002), alpha Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci U S A 99:10813–10818.
26. Magen I, Chesselet MF (2011) Mouse models of cognitive deficits due to alpha-synuclein pathology. J Parkinsons Dis 1:217–227.
27. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, Al-Hayani A, Davies SN, Rasband MN, Olsson T, Moldenhauer A, Velhin S, Hohlfeld R, Meinl E, Linington C (2007) Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204:2363–2372.
28. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110: 1429–1439.
29. Niu Y, Guo X, Chen Y, Wang CE, Gao J, Yang W, Kang Y, Si W, Wang H, Yang SH, et al. (2015) Early Parkinson’s disease symptoms in alpha-synuclein transgenic monkeys. 24:2308–2317.
30. Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson’s disease. Annu Rev Neurosci 22:123–144.
31. Piao YS, Mori F, Hayashi S, Tanji K, Yoshimoto M, Kakita A, Wakabayashi K, Takahashi H (2003) Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. Acta Neuropathol 105:403–409.
32. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56:173–181.
33. Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE, Giasson BI (2014) Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34:12368–12378.
34. Sherman DL, Tait S, Melrose S, Johnson R, Zonta B, Court FA, Macklin WB, Meek S, Smith AJ, Cottrell DF, Brophy PJ (2005) Neurofascins are required to establish axonal domains for saltatory conduction. Neuron 48: 737–742.
35. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, aptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (2003) Alpha-synuclein locus triplication causes Parkinson’s disease. Science 302:841.
36. Spillantini MG, Crowther RA, Jakes R, Hasegawa M Goedert M (1998), alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95:6469–6473.
37. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA (2001) Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21:9549–9560.
38. Stiasny-Kolster K, Doerr Y, Möller JC, Höffken H, Behr TM, Oertel WH, Mayer G (2005) Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126–137.
39. Vierck JL, Bryne KM, Dodson MV (2000) Evaluating dot and Western blots using image analysis and pixel quantification of electronic images. Methods Cell Sci 22:313–318.
40. Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, Li S, Chan AW, Li XJ (2008) Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington’s disease. Hum Mol Genet 17:2738–2751.
41. Xie W, Li X, Li C, Zhu W, Jankovic J, Le W (2010) Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease. J Neurochem 115:188–199.
42. Yin P, Tu Z, Yin A, Zhao T, Yan S, Guo X, Chang R, Zhang L, Hong Y, Huang X, Zhou J, Wang Y, Li S, Li XJ (2015) Aged monkey brains reveal the role of ubiquitin-conjugating enzyme UBE2N in the synaptosomal accumulation of mutant huntingtin. Hum Mol Genet 24:1350–1362.
43. Zhang X, Davis JQ, Carpenter S, Bennett V (1998) Structural requirements for association of neurofascin with ankyrin. J Biol Chem 273:30785– 30794.